Bioretec’s Board of Directors has appointed Sarah van Hellenberg Hubar-Fisher as interim CEO, effective immediately. Management will continue to search for a new CEO.

“CEO Sarah van Hellenberg Hubar-Fisher starts the new growth phase for Bioretec. She brings over 23 years of global healthcare leadership and new technology introduction experience, and we are keen to leverage that expertise in bringing Bioretec to the next level with the aim of becoming a leader in absorbable orthopedic implants globally,” Board Chair Kustaa Poutiainen said.

Van Hellenberg Hubar-Fisher will remain a board member and participant of the Audit Committee. In light of van Hellenberg Hubar-Fisher’s appointment, the board is transferring the Remuneration Committee’s duties to the entire governing body until further notice.

“I could not be more enthusiastic about the next phases of growth for Bioretec and the opportunity to lead us there,” van Hellenberg Hubar-Fisher stated. “Bioretec is poised to aim for market leadership, and our organization is ready to promote its realization for the patients who deserve and have been waiting for high-quality and reliable absorbable implants.”

Bioretec is commercializing and developing the new RemeOs product line based on a magnesium alloy and hybrid composite, a new generation of strong biodegradable materials for enhanced surgical outcomes. RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination could potentially make titanium implants redundant and help clinics reach their value-based healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs product to receive U.S. Food and Drug Administration occurred in March 2023; CE mark approval followed in January 2025. Bioretec is positioning itself to enter the $9 billion-plus global orthopedic trauma and spine market and become a major player in surgical bone fracture treatment.

Bioretec is a Finnish medical device company pioneering the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.